University of Pennsylvania

Overview

The PhD program in Cell and Molecular Biology at the University of Pennsylvania, with a focus on Gene Therapy and Vaccines, is designed to equip students with the skills to explore the use of gene transfer and immunological mechanisms in disease prevention and treatment. This comprehensive program emphasizes a robust foundation in cell and molecular biology, combined with extensive research training through coursework, seminars, and laboratory experiences.

What you'll study

Training approach: The program integrates coursework and seminars to build foundational knowledge, while lab rotations and dissertation research foster in-depth expertise in gene therapy and vaccine-related topics.

• First-year seminar: CAMB First Year Seminar
• Core cell and molecular biology: Cell Biology; Regulation of the Genome
• Gene therapy and genome engineering: Molecular Basis of Gene Therapy and Genome Editing
• Laboratory training: Lab Rotation to explore various research groups and methodologies
• Immunology foundations: Immunology; Immune Mechanisms
• Research methods: Statistics; Scientific Writing
• Advanced learning: Survey course in gene therapy and vaccines, supplemented by advanced seminars focused on specific topics in these fields

Dissertation: Students are required to complete a PhD dissertation based on original research conducted under faculty supervision, culminating in a formal dissertation defense, with specific details dependent on departmental requirements and the dissertation committee.

Entry requirements

While specific GRE/GMAT scores and GPA minimums are not detailed, applicants are encouraged to demonstrate strong academic performance and research potential in their applications. English proficiency is required for non-native speakers.

Career prospects

Graduates of this PhD program can pursue various career paths in academia, industry, and research institutions. Opportunities may include positions in biomedical research, pharmaceutical development, public health, and regulatory agencies, focusing on advancements in gene therapy and vaccine technology.